Gilead to license technology from EVOQ to develop RA, lupus immunotherapies
peterschreiber.media



Gilead Sciences (NASDAQ:GILD) has signed a licensing agreement with EVOQ Therapeutics to gain access to the latter's NanoDisc technology for the development of immunotherapies for rheumatoid arthritis and lupus.
EVOQ is eligible for up to $658.5M in upfront and milestone payments, as well as tiered royalties under the deal.

The NanoDisc technology "is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases," according to the companies.
Gilead (GILD) currently has the IRAK4 inhibitor GS-5718 in phase 1 for both rheumatoid arthritis and lupus.
Read why Seeking Alpha contributor Giesbers Investment Strategy rates Gilead a hold.